Warning letter
BEO Pharma Inc. dba BEO Pharmaceuticals Inc.: warning letter of Apr 9, 2025
FDA warning letter 701364 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 701364 |
|---|---|
| Company | BEO Pharma Inc. dba BEO Pharmaceuticals Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Apr 9, 2025 |
| Posted date | Apr 29, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.165(a), 211.22(a), 211.34, 211.84(d)(1), 211.100(a), 211.160(b) |
| Inspection city | Brooksville |
| Inspection ZIP | 34604 |
| Inspection start date | Oct 16, 2024 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: